Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) saw unusually large options trading on Tuesday. Stock investors bought 11,366 put options on the stock. This is an increase of approximately 247% compared to the average daily volume of 3,275 put options.

Omeros Stock Performance

OMER stock opened at $10.50 on Wednesday. The company has a market capitalization of $759.99 million, a PE ratio of 15.00 and a beta of 2.55. Omeros has a one year low of $3.34 and a one year high of $17.65. The company’s 50 day moving average price is $10.95 and its two-hundred day moving average price is $11.84.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $4.19 million. On average, research analysts predict that Omeros will post -0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on OMER. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. Weiss Ratings lowered shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 2nd. HC Wainwright reduced their target price on Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Finally, Zacks Research upgraded Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Insider Buying and Selling at Omeros

In related news, Director Thomas J. Cable sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the transaction, the director directly owned 35,067 shares in the company, valued at approximately $407,127.87. This represents a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.50% of the company’s stock.

Institutional Trading of Omeros

Hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new position in shares of Omeros during the first quarter valued at about $357,000. XTX Topco Ltd bought a new stake in shares of Omeros in the 2nd quarter valued at about $191,000. Invesco Ltd. boosted its holdings in Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after acquiring an additional 29,644 shares during the period. Marshall Wace LLP boosted its holdings in Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after acquiring an additional 97,224 shares during the period. Finally, Sei Investments Co. bought a new position in Omeros during the 2nd quarter worth approximately $40,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.